Evaluation of immunogenicity and safety of a booster dose of Infanrix hexa™ in healthy infants born to mothers vaccinated with Boostrix™ during pregnancy or immediately post-delivery

Trial Identifier: 201334
Sponsor: GlaxoSmithKline
Start Date: September 2016
Primary Completion Date: March 2019
Condition: Hepatitis B

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, Victoria Carlton, Victoria, Australia, 3053
Canada, Alberta Calgary, Alberta, Canada, T3B 6A8
Canada, Nova Scotia Halifax, Nova Scotia, Canada, B3K 6R8
Canada, Québec Montreal, Québec, Canada, H3T 1C5
Czech Republic Brno, Czech Republic, 613 00
Czech Republic Hradec Kralove, Czech Republic, 500 02
Czech Republic Ostrava - Vitkovice, Czech Republic, 703 84
Czech Republic Praha, Czech Republic, 14700
Czech Republic Praha 4, Czech Republic, 140 59
Finland Kokkola, Finland, 67100
Finland Oulu, Finland, 90220
Finland Seinajoki, Finland, 60100
Finland Tampere, Finland, 33100
Finland Turku, Finland, 20520
Italy, Lombardia Milano, Lombardia, Italy, 20122
Italy, Lombardia Milano, Lombardia, Italy, 20154
Italy, Lombardia Milano, Lombardia, Italy, 20142
Italy, Piemonte Novara, Piemonte, Italy, 28100
Spain Antequera/Málaga, Spain, 29200
Spain Aravaca, Spain, 28023
Spain Burgos, Spain, 09006
Spain Madrid, Spain, 28046
Spain Madrid, Spain, 28040
Spain Majadahonda (Madrid), Spain, 28222
Spain Móstoles, Spain, 28938
Spain Santiago de Compostela, Spain, 15706
Spain Sevilla, Spain, 41014
Spain, Andalucia Malaga, Andalucia, Spain, 29004
Spain, Madrid Madrid, Spain, 28050